IDXX 144.58 Idexx Laboratories $IDXX Hit a 52 week high of 145.99 Currently at 144.58 -0.58 -0.40% With a day low of 144.71 and a total volume of 16,468.
IDXX Idexx Laboratories Recent Headline News
Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 146.29 (+1.13)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 187.01 (+0.86), GE: 26.46 (+0.05), BMRN: 87.17 (+3.26), IDXX: 146.29 (+1.13), GSK: 45.25 (+0.34), NVS: 92.41 (+0.65)
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 146.29 (+1.13)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.43 (+0.04), EW: 123.58 (+0.82), IDXX: 146.29 (+1.13), ANGO: 16.94 (-0.01)
Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 146.29 (+1.13)
IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 146.29 (+1.13)
Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 146.29 (+1.13)
Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 146.29 (+1.13)
IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"
for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05.
IDXX: 146.29 (+1.13)
Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 146.29 (+1.13), ORCL: 40.26 (+0.32)
IDEXX Laboratories to Release 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 14, 12:45PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 third quarter financial results for Friday, October 24, 2014 at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 146.29 (+1.13)
IDEXX Laboratories Poised on Strong CAG Growth Globally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 5:40PM CDT
On Oct 7, 2014, we updated our research report on IDEXX Laboratories, Inc. (IDXX).
HNSN: 0.80 (-0.03), EW: 123.58 (+0.82), IDXX: 146.29 (+1.13), HOLX: 26.42 (+0.21)
Idexx Laboratories (IDXX) Marked As A Barbarian At The Gate
at The Street - Wed Oct 01, 2:02PM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
IDXX: 146.29 (+1.13)
IDEXX Announces Several Milestones in its US All-Direct CAG Distribution Strategy
PR Newswire - Wed Oct 01, 9:29AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that it had selected United Parcel Service (UPS) to provide third party logistic services in support of its strategy to go all-direct with US companion animal veterinary practices. This agreement builds on IDEXX's distribution and logistics capability, and provides for five warehouse and shipping locations strategically located across the US, three of which are provided by UPS' third party logistics services.
IDXX: 146.29 (+1.13)
Idexx Laboratories Shares Down 11.7% Since SmarTrend's Sell Call (IDXX)
Comtex SmarTrend(R) - Mon Sep 22, 5:23PM CDT
SmarTrend identified a Downtrend for Idexx Laboratories (NASDAQ:IDXX) on July 28th, 2014 at $129.81. In approximately 2 months, Idexx Laboratories has returned 11.66% as of today's recent price of $114.67.
IDXX: 146.29 (+1.13)
Watch for Idexx Laboratories to Potentially Rebound After Falling 2.51% Yesterday
Comtex SmarTrend(R) - Fri Sep 19, 4:21PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $116.47 to a high of $121.12. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $119.68 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IDXX: 146.29 (+1.13)
Idexx Laboratories (IDXX) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Sep 19, 9:02AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
IDXX: 146.29 (+1.13)
IDEXX Laboratories names Jacqueline L. Studer as corporate VP
M2 - Fri Sep 19, 6:31AM CDT
Healthcare company IDEXX Laboratories (NasdaqGS:IDXX) said on Friday that Jacqueline L. Studer has been named as its corporate vice president, general counsel and secretary.
IDXX: 146.29 (+1.13)
IDEXX Laboratories Names Jacqueline L. Studer Corporate Vice President and General Counsel
PR Newswire - Thu Sep 18, 4:31PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces today the appointment of Jacqueline L. Studer as Corporate Vice President, General Counsel and Secretary, effective September 1. Ms. Studer leads the Legal, Compliance, Regulatory Affairs and Quality Assurance groups.
IDXX: 146.29 (+1.13)
Global Veterinary Diagnostics Market 2014-2018 Featuring Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech & Zoetis
M2 - Thu Sep 04, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9m9mv/global_veterinary) has announced the addition of the "Global Veterinary Diagnostics Market 2014-2018" report to their offering. The Global Veterinary Diagnostics market to grow at a CAGR of 8.10 percent over the period 2013-2018. Veterinary diagnostics include various tests, which are used to detect diseases in animals. Veterinarians, pet owners, livestock producers, and biomedical researchers are mainly availing these diagnostic services. Major diagnostic methods include molecular testing (Deoxyribonucleic Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, and hematology. These tests are executed through blood, urine, tissue, and feces samples from animals. The Global Veterinary Diagnostics market is expected to grow steadily during the forecast period of 2014-2018 because of the presence of early animal molecular diagnostics tests that execute rapid diagnosis for a wide variety of diseases. Advances in technology in laboratory equipment have led to tests to detect challenging diseases in animals. According to the report, the increasing diagnosis of diseases in animals as a result of advances in technology is one of the major drivers of this market. The outbreak of diseases among animals and their spread to humans, leading to the threat of epidemics worldwide, is a major concern. Further, the report states that one of the major challenges in the market is low animal healthcare expenditure because of the economic downturn. This has caused changes in concern over the health of animals, resulting in negligence in their treatment. To calculate the market size, the report considers the revenue generated through the following five segments: - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Key Vendors - Abaxis - Heska - IDEXX Laboratories - Mindray Medical - VCA Antech - Zoetis Other Prominent Vendors - Neogen - Thermo Fisher Scientific - Virbac For more information visit http://www.researchandmarkets.com/research/k9...veterinary
ABAX: 52.66 (+1.03), NEOG: 43.79 (+0.78), IDXX: 146.29 (+1.13)
IDXX Idexx Laboratories Recent Headline News
Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 146.29 (+1.13)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 187.01 (+0.86), GE: 26.46 (+0.05), BMRN: 87.17 (+3.26), IDXX: 146.29 (+1.13), GSK: 45.25 (+0.34), NVS: 92.41 (+0.65)
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 146.29 (+1.13)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.43 (+0.04), EW: 123.58 (+0.82), IDXX: 146.29 (+1.13), ANGO: 16.94 (-0.01)
Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 146.29 (+1.13)
IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 146.29 (+1.13)
Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 146.29 (+1.13)
Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 146.29 (+1.13)
IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"
for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05. IDXX: 146.29 (+1.13)
Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 146.29 (+1.13), ORCL: 40.26 (+0.32)
IDEXX Laboratories to Release 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 14, 12:45PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 third quarter financial results for Friday, October 24, 2014 at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 146.29 (+1.13)
IDEXX Laboratories Poised on Strong CAG Growth Globally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 5:40PM CDT
On Oct 7, 2014, we updated our research report on IDEXX Laboratories, Inc. (IDXX).
HNSN: 0.80 (-0.03), EW: 123.58 (+0.82), IDXX: 146.29 (+1.13), HOLX: 26.42 (+0.21)
Idexx Laboratories (IDXX) Marked As A Barbarian At The Gate
at The Street - Wed Oct 01, 2:02PM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
IDXX: 146.29 (+1.13)
IDEXX Announces Several Milestones in its US All-Direct CAG Distribution Strategy
PR Newswire - Wed Oct 01, 9:29AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that it had selected United Parcel Service (UPS) to provide third party logistic services in support of its strategy to go all-direct with US companion animal veterinary practices. This agreement builds on IDEXX's distribution and logistics capability, and provides for five warehouse and shipping locations strategically located across the US, three of which are provided by UPS' third party logistics services.
IDXX: 146.29 (+1.13)
Idexx Laboratories Shares Down 11.7% Since SmarTrend's Sell Call (IDXX)
Comtex SmarTrend(R) - Mon Sep 22, 5:23PM CDT
SmarTrend identified a Downtrend for Idexx Laboratories (NASDAQ:IDXX) on July 28th, 2014 at $129.81. In approximately 2 months, Idexx Laboratories has returned 11.66% as of today's recent price of $114.67.
IDXX: 146.29 (+1.13)
Watch for Idexx Laboratories to Potentially Rebound After Falling 2.51% Yesterday
Comtex SmarTrend(R) - Fri Sep 19, 4:21PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $116.47 to a high of $121.12. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $119.68 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IDXX: 146.29 (+1.13)
Idexx Laboratories (IDXX) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Sep 19, 9:02AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
IDXX: 146.29 (+1.13)
IDEXX Laboratories names Jacqueline L. Studer as corporate VP
M2 - Fri Sep 19, 6:31AM CDT
Healthcare company IDEXX Laboratories (NasdaqGS:IDXX) said on Friday that Jacqueline L. Studer has been named as its corporate vice president, general counsel and secretary.
IDXX: 146.29 (+1.13)
IDEXX Laboratories Names Jacqueline L. Studer Corporate Vice President and General Counsel
PR Newswire - Thu Sep 18, 4:31PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces today the appointment of Jacqueline L. Studer as Corporate Vice President, General Counsel and Secretary, effective September 1. Ms. Studer leads the Legal, Compliance, Regulatory Affairs and Quality Assurance groups.
IDXX: 146.29 (+1.13)
Global Veterinary Diagnostics Market 2014-2018 Featuring Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech & Zoetis
M2 - Thu Sep 04, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9m9mv/global_veterinary) has announced the addition of the "Global Veterinary Diagnostics Market 2014-2018" report to their offering. The Global Veterinary Diagnostics market to grow at a CAGR of 8.10 percent over the period 2013-2018. Veterinary diagnostics include various tests, which are used to detect diseases in animals. Veterinarians, pet owners, livestock producers, and biomedical researchers are mainly availing these diagnostic services. Major diagnostic methods include molecular testing (Deoxyribonucleic Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, and hematology. These tests are executed through blood, urine, tissue, and feces samples from animals. The Global Veterinary Diagnostics market is expected to grow steadily during the forecast period of 2014-2018 because of the presence of early animal molecular diagnostics tests that execute rapid diagnosis for a wide variety of diseases. Advances in technology in laboratory equipment have led to tests to detect challenging diseases in animals. According to the report, the increasing diagnosis of diseases in animals as a result of advances in technology is one of the major drivers of this market. The outbreak of diseases among animals and their spread to humans, leading to the threat of epidemics worldwide, is a major concern. Further, the report states that one of the major challenges in the market is low animal healthcare expenditure because of the economic downturn. This has caused changes in concern over the health of animals, resulting in negligence in their treatment. To calculate the market size, the report considers the revenue generated through the following five segments: - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Key Vendors - Abaxis - Heska - IDEXX Laboratories - Mindray Medical - VCA Antech - Zoetis Other Prominent Vendors - Neogen - Thermo Fisher Scientific - Virbac For more information visit http://www.researchandmarkets.com/research/k9...veterinary
ABAX: 52.66 (+1.03), NEOG: 43.79 (+0.78), IDXX: 146.29 (+1.13)
